Bispecific antibody specifically binding to GPNMB and CD3, and use thereof
US12319746B2 · kind B2 · utility
0Cited by
0References
24Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 6, 2020 |
| Grant date | Jun 3, 2025 |
| Priority date | — |
| Expiry date | Oct 3, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A bispecific anti-GPNMB/anti-CD3 antibody specifically binds to CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B) and uses thereof are disclosed. The bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.